KFA
CRVS icon

Kelleher Financial Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Kelleher Financial Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12K Buy
+75
New +$1.04K ﹤0.01% 799
2026
Q1 		– Sell
-75
Closed -$578 – 690
2025
Q4 		$578 Hold
75
– – ﹤0.01% 681
2025
Q3 		$553 Buy
+75
New +$384 ﹤0.01% 622

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Kelleher Financial Advisors's CRVS Position: Q2 2026 in Review

Kelleher Financial Advisors opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 75 shares worth $1.12K. The stake represents ﹤0.01% of the portfolio and ranks #799 among its holdings. This is a return to the name: Kelleher Financial Advisors previously reported a position in CRVS as recently as Q4 2025.

Kelleher Financial Advisors first reported a position in CRVS in Q3 2025 and has held it in 3 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Kelleher Financial Advisors held 75 shares of Corvus Pharmaceuticals worth $1.12K as of Q2 2026.
  • Corvus Pharmaceuticals was a new Kelleher Financial Advisors position in Q2 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Kelleher Financial Advisors's portfolio in Q2 2026, its #799 holding.
  • Kelleher Financial Advisors first reported a position in Corvus Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Kelleher Financial Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.